Patent ID: 11884748
Assignee: PROTAGONIST THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C

Claim 0:
1. A pharmaceutical composition comprising a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent,
wherein the peptide inhibitor of an interleukin-23 receptor is selected from the group consisting of:, (SEQ ID NO: 702)

Ac-[Abta]-QTWQC-[Phe(4-OMe)]-[2-Nal]-[α-Me-Lys]-

 

ENG-NH2; 

 

(SEQ ID NO: 704)

Ac-[Abta]-QTWQCY-[2-Nal]-[α-Me-Lys]-ENG-NH2; 

 

(SEQ ID NO: 782)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]-W-

 

[α-Me-Lys]-ENG-NH2;

 

(SEQ ID NO: 861)

Ac-[Abta]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-Me-Lys]-[Lys(isovaleric acid)]-NG-NH2; 

 

(SEQ ID NO: 877)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]

 

AiN-QNG-NH2;

 

(SEQ ID NO: 880)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[AibMLys(Ac)]-NA-NH2; 

 

(SEQ ID NO: 900)

Ac-[Abu]-QTWQC-[Phe[4-(2-(acetyl-aminoethoxy)]]-

 

[2-Nal]-[α-Me-Lys(Ac)]-[Lys(Ac)]-NG-NH2; 

 

(SEQ ID NO: 911)

Ac-[Abta]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-Me-Lys]-ENQ-NH2; 

 

(SEQ ID NO: 912)

Ac-[Abta]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-Me-Lys]-ENN-NH2; 

 

(SEQ ID NO: 915)

Ac-[Abta]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-MeVal]-[Lys(Ac)]-NG-NH2;

 

(SEQ ID NO: 954)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-Me-Leu]-[Cit]-NN-NH2; 

 

(SEQ ID NO: 970)

Ac-[(D)Phe]-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-

 

[2-Nal]-[α-Me-Lys]-ENN-NH2; 

 

(SEQ ID NO: 972)

Ac-T-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[α-Me-Lys]-ENN-NH2; 

 

(SEQ ID NO: 976)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-

 

[2-Nal]-[acbc]-ENN-NH2;

 

(SEQ ID NO: 980)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-

 

[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]-

 

ENN-NH2;

 

(SEQ ID NO: 984)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[alphα-methyl-L-Leucine]-QN-[betaAla]-NH2;

 

(SEQ ID NO: 992)

Ac-(D)Phe-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-

 

[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]- 

 

ENN-NH2;

 

(SEQ ID NO: 993)

Ac-[(D)Arg]-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-

 

[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]-

 

ENN-NH2; 

 

(SEQ ID NO: 1043) 

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-

 

[acpc]-ENN-NH2; 

or

 

(SEQ ID NO: 1047)

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]

 

achc]-ENN-NH2;, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.